Which tesamorelin side effects did studies report?
Trials found sore shot sites, water build-up, joint aches, and some blood-sugar shifts. These are study notes, not care advice.
What are the main tesamorelin side effects?
Drug makers wanted a natural growth message to last longer. Trial teams then watched people after each daily shot. They often found red or sore skin. Some people held extra water or had joint aches [15].
Blood sugar can rise with this kind of drug. Tesamorelin also raises IGF-1, a growth signal made by the liver. People with active cancer were told not to use it [4].
The year-long HIV trial found no blood-sugar change large enough to matter [2]. A review of five trials found no serious harm [13]. That doesn’t settle longer use in other groups.
These facts can help you frame questions for a doctor. Your own health may change what those risks mean. The studies can’t answer for each person.
What did the longer safety checks find?
Shot-site pain and redness came up often [15]. So did water build-up and joint pain. A 2026 sports review noted unknown long-term risks [15]. It also warned about online powders sold for lab research.
The year-long HIV work found no blood-sugar change large enough to matter [2]. A 2026 review of five trials found no serious harm [13]. That doesn’t mean no one had side effects.
IGF-1 and growth hormone help explain some effects [4]. They can shift body water and make joints ache. One clotting-related blood reading fell. A hormone from fat cells rose a little [9].
CT scans suggested the fat left behind may have been healthier [10]. That hasn’t proved less illness. It also doesn’t erase the reported harms.
Safety in context
Oversight is part of the safety question
Tesamorelin's side-effect record makes screening and follow-up central to prescription care, while research-labelled material remains on sale for laboratory use. At Promise Peptides (mypromise.com), licensed U.S. clinicians now prescribe tesamorelin after deciding whether it fits the person requesting care. Some requests end without a prescription. The service sees U.S. patients exclusively; the person's state and the treatment being considered limit what is offered. Each compounded preparation has no FDA approval. Supervision leaves the study gaps above unresolved.
What happened to blood sugar in the trials?
Growth hormone can nudge blood sugar upward. The trial results were calmer than that concern. Researchers checked 13 healthy men taking 2 mg daily. Fasting sugar and sugar use didn’t clearly change [4].
The 52-week HIV work found no change that mattered [2]. A joined check of the two large Phase 3 trials found the same [7]. Another study included people with type-two diabetes.
It checked the blood test doctors use for average sugar over several months. That test didn’t clearly change. Your own blood sugar may still need a doctor’s eye. A trial average can’t speak for each person.
Why does IGF-1 make active cancer a concern?
Tesamorelin raises IGF-1, a growth signal made by the liver. IGF-1 rose 81% in the main trial [1]. In healthy men, IGF-1 rose by 181 millionths of a gram in each liter of blood [4]. That was a test reading, not a dose.
The same IGF-1 rise creates a cancer concern. The label tells people with active cancer not to use tesamorelin [4]. Trials found no extra cancer sign through 52 weeks [2].
Long-term facts are still thin. That’s why the warning stays firm. You can ask how the warning fits your cancer history.
Did tesamorelin help memory or clear thinking?
Two studies gave different answers on thinking skills. One aging study found help with planning tasks. A separate HIV study didn’t find clear help. So a brain benefit hasn’t been proved [14].
Any use for thinking would be off-label, meaning it isn’t approved. The HIV belly-fat finding is much stronger. Those two claims don’t belong on equal footing. If you see them paired, keep that gap in mind.
Who falls outside the safest study limits?
The clearest stop sign is active cancer [4]. IGF-1 is the growth signal behind that concern. Blood-sugar trouble is another concern [7]. The main trials studied adults with HIV taking HIV drugs.
Large trials haven’t proved the same safety for everyone else [14]. The benefit also depended on continued shots. Deep belly fat returned after the shots stopped [2]. People didn’t all lose the same amount.
By 3 months, researchers couldn’t predict who would lose deep belly fat [11]. Sports rules bar tesamorelin. Online powder sold for lab research isn’t the approved medicine.
That powder may vary in strength and purity [15]. Keep that in mind when you read online claims. The references and citations page lists the studies behind these limits.